Alexis Peyroles

Alexis joined OSE Immunotherapeutics in September 2013 as Chief Financial Officer and Chief Operating Officer.

He became Director and Deputy CEO in charge of finance, business development, and operations in May 2016, then CEO in April 2018.

For personal reasons, he stepped down from his CEO position and Board mandate in January 2022.

Since leaving OSE, Alexis has co-founded two biotech companies, Inside Therapeuticsand OWL Lifesciences, where he chairs the Strategic Committees.

He is now CEO of BetaGlue a biotech specialised in nuclear medecine

Before OSE, he was Head of Management Control, then South America Director at Guerbet(medical imaging). Previously, he worked within Hoechst Marion Roussel (now Sanofi) in Japan, in the Baltic countries, then across the entire Eastern Europe zone.

Through his experiences in France and internationally, Alexis has built major expertise in growth strategies, fundraising, licensing agreements, leading multicultural teams, and improving operational management.

He is a graduate of EDHEC and holds an Executive MBA from Imperial College London.